A Phase 2 interventional study of CDC-501 in Multiple Myeloma, sponsored by Celgene. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-12.
Sponsored by Celgene · Phase 2, Interventional, and Treatment
The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.
3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.
This study's enrollment of 102 is above the median of 41 across 2,907 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Celgene is the lead sponsor of 419 studies on the registry; 13 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 29 (29%) have results posted.
Counted across the registry records on this site, refreshed daily.
Confirmed M-Protein Response During Single Agent CDC-501 Therapy
M-Protein response evaluated every 4 weeks through urine and serum electrophoresis.
Time frame: Response assessed every 4 weeks; up to 62 months
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Celgene